Incidence of new-onset type 2 diabetes after cancer: A Danish cohort study
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Standard
Incidence of new-onset type 2 diabetes after cancer: A Danish cohort study. / Sylow, Lykke; Grand, Mia Klinten; von Heymann, Annika; Persson, Frederik; Siersma, Volkert; Kriegbaum, Margit; Lykkegaard Andersen, Christen; Johansen, Christoffer.
I: Diabetes Care, Bind 45, Nr. 6, 2022, s. e105-e106.Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Incidence of new-onset type 2 diabetes after cancer: A Danish cohort study
AU - Sylow, Lykke
AU - Grand, Mia Klinten
AU - von Heymann, Annika
AU - Persson, Frederik
AU - Siersma, Volkert
AU - Kriegbaum, Margit
AU - Lykkegaard Andersen, Christen
AU - Johansen, Christoffer
N1 - CURIS 2022 NEXS 144
PY - 2022
Y1 - 2022
N2 - For patients with cancer, prevalent type 2 diabetes at the date of cancer diagnosis is associated with increased cancerspecific and all-cause mortality (1,2). Yet, despite potential health implications, there is limited knowledge on whether cancer is also a risk factor for type 2 diabetes. Moreover, the impact of new-onset type 2 diabetes after cancer diagnosis on survival among cancer patients is unknown. We investigated the incidence of type 2 diabetes following a cancer diagnosis and evaluated the influence of new-onset type 2 diabetes in patients with cancer onoverall survival.
AB - For patients with cancer, prevalent type 2 diabetes at the date of cancer diagnosis is associated with increased cancerspecific and all-cause mortality (1,2). Yet, despite potential health implications, there is limited knowledge on whether cancer is also a risk factor for type 2 diabetes. Moreover, the impact of new-onset type 2 diabetes after cancer diagnosis on survival among cancer patients is unknown. We investigated the incidence of type 2 diabetes following a cancer diagnosis and evaluated the influence of new-onset type 2 diabetes in patients with cancer onoverall survival.
U2 - 10.2337/dc22-0232
DO - 10.2337/dc22-0232
M3 - Letter
C2 - 35653597
VL - 45
SP - e105-e106
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 6
ER -
ID: 308553167